Twice-daily chemoradiotherapy must still be the choice for patients with limited-stage small-cell lung cancer

Antzeko izenburuak

• Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
  nork: Faivre-Finn, Corinne, et al.
  Argitaratua: (2017)
• A Meta-Analysis of the Efficacy and Toxicity of Twice-Daily vs. Once-Daily Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer Based on Randomized Controlled Trials
  nork: Wu, Qian, et al.
  Argitaratua: (2020)
• Comparison of once daily radiotherapy to 60 Gy and twice daily radiotherapy to 45 Gy for limited stage small-cell lung cancer
  nork: Han, Dan, et al.
  Argitaratua: (2015)
• A Comparison of Hypofractionated and Twice-Daily Thoracic Irradiation in Limited-Stage Small-Cell Lung Cancer: An Overlap-Weighted Analysis
  nork: Yan, Michael, et al.
  Argitaratua: (2021)
• Protocol for the CONVERT trial—Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status
  nork: Faivre-Finn, Corinne, et al.
  Argitaratua: (2016)